

John A Bridgewater

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2005538/publications.pdf>

Version: 2024-02-01

92
papers

17,151
citations

71004

43
h-index

62345

84
g-index

98
all docs

98
docs citations

98
times ranked

15539
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	13.9	3,370
2	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2343-2351.	13.9	3,268
3	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
4	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	1.8	1,151
5	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet</i> , The, 2011, 377, 2103-2114.	6.3	876
6	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 663-673.	5.1	773
7	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	5.1	620
8	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 690-701.	5.1	396
9	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 601-611.	5.1	371
10	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 627-637.	5.1	346
11	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. <i>Annals of Oncology</i> , 2014, 25, 391-398.	0.6	314
12	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015, 26, 702-708.	0.6	271
13	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study " The UK ABC-01 Study. <i>British Journal of Cancer</i> , 2009, 101, 621-627.	2.9	243
14	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 862-873.	5.1	239
15	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363.	1.8	235
16	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 967-978.	5.1	221
17	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	3.4	194
18	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	1.1	182

#	ARTICLE	IF	CITATIONS
19	Guidance on the management of diarrhoea during cancer chemotherapy. <i>Lancet Oncology</i> , The, 2014, 15, e447-e460.	5.1	171
20	ABC-06 A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4003-4003.	0.8	166
21	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 398-411.	5.1	152
22	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4006-4006.	0.8	142
23	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 562-578.	5.1	133
24	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e194-e203.	1.8	126
25	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	7.7	119
26	Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. <i>British Journal of Cancer</i> , 2008, 98, 1425-1430.	2.9	96
27	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
28	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	0.8	92
29	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	3.0	90
30	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016, 27, 134-140.	0.6	88
31	Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170.	3.4	85
32	Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. <i>Annals of Oncology</i> , 2016, 27, 687-692.	0.6	82
33	Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. <i>Annals of Oncology</i> , 2012, 23, 298-304.	0.6	79
34	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	3.4	73
35	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	0.8	65
36	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. <i>BMC Cancer</i> , 2016, 16, 153.	1.1	62

#	ARTICLE	IF	CITATIONS
37	Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. <i>Annals of Oncology</i> , 2015, 26, 1910-1916.	0.6	61
38	FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> gene fusions or other rearrangements.. <i>Journal of Clinical Oncology</i> , 2020, 38, 108-108.	0.8	61
39	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. <i>Targeted Oncology</i> , 2017, 12, 97-109.	1.7	56
40	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	3.7	51
41	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	5.2	50
42	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 854-862.	3.7	47
43	Outcome of second-line chemotherapy for biliary tract cancer. <i>European Journal of Cancer</i> , 2013, 49, 1511.	1.3	45
44	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. <i>Oncotarget</i> , 2017, 8, 93856-93866.	0.8	42
45	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. <i>British Journal of Cancer</i> , 2016, 114, 965-971.	2.9	39
46	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	2.9	37
47	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	2.6	36
48	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. <i>Health Technology Assessment</i> , 2019, 23, 1-270.	1.3	34
49	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775.	3.7	33
50	The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 154-159.	0.3	30
51	Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095680.	1.4	29
52	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010.	0.4	28
53	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015, 51, 1694-1703.	1.3	25
54	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25

#	ARTICLE	IF	CITATIONS
55	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and) Tj ETQq1 1 0.784314 rgnBT /Overlo	2.3	20
56	Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment. <i>European Radiology</i> , 2019, 29, 3889-3900.	2.3	20
57	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020, 123, 709-713.	2.9	20
58	PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. <i>ESMO Open</i> , 2018, 3, e000379.	2.0	20
59	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	20
60	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018, 119, 27-35.	2.9	19
61	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
62	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021, 26, e669-e678.	1.9	15
63	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1760-1768.	2.9	14
64	Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 267-271.	0.6	13
65	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	6.1	11
66	New advances in the management of biliary tract cancer. <i>Hpb</i> , 2007, 9, 104-111.	0.1	9
67	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. <i>British Journal of Cancer</i> , 2016, 115, 420-424.	2.9	9
68	Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomesâ€”The University College London Hospital (UCLH) Experience. <i>Cancers</i> , 2020, 12, 3545.	1.7	9
69	Adjuvant therapy for resected gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 39-39.	0.4	7
70	A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08). <i>Annals of Oncology</i> , 2018, 29, viii259.	0.6	6
71	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS468-TPS468.	0.8	6
72	Photodynamic therapy for biliary tract cancer. <i>British Journal of Surgery</i> , 2009, 96, 225-226.	0.1	4

#	ARTICLE	IF	CITATIONS
73	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. Journal of Clinical Oncology, 2014, 32, 3523-3523.	0.8	3
74	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. Journal of Clinical Oncology, 2014, 32, 3556-3556.	0.8	3
75	ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. Journal of Clinical Oncology, 2014, 32, 4002-4002.	0.8	3
76	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4025-4025.	0.8	3
77	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open, 2022, 7, 100417.	2.0	3
78	How should we drain malignant obstruction at the liver hilum?. The Lancet Gastroenterology and Hepatology, 2018, 3, 657-658.	3.7	2
79	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. Cancers, 2020, 12, 2375.	1.7	2
80	Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?. Annals of Oncology, 2020, 31, 447-448.	0.6	2
81	Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision. BMC Cancer, 2017, 17, 365.	1.1	1
82	Hepatic metastases resection after cetuximab: are we missing something? â€œ Authors' reply. Lancet Oncology, The, 2020, 21, e229.	5.1	1
83	Analysis of progression-free survival in the new EPOC study in an â€œall wild-typeâ€ population.. Journal of Clinical Oncology, 2014, 32, 3566-3566.	0.8	1
84	Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.. Journal of Clinical Oncology, 2016, 34, 118-118.	0.8	1
85	Reply to J. Edeline et al. Journal of Clinical Oncology, 0, , .	0.8	1
86	Systemic treatment of biliary tract cancer: now we have the evidence. Annals of Oncology, 2019, 30, 1851-1852.	0.6	0
87	Reply to Comment on â€œThe UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemicâ€ British Journal of Cancer, 2021, 124, 679-680.	2.9	0
88	Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts).. Journal of Clinical Oncology, 2014, 32, 294-294.	0.8	0
89	Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-related quality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.. Journal of Clinical Oncology, 2014, 32, 4126-4126.	0.8	0
90	ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, 4090-4090.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3653-TPS3653.	0.8	0
92	Prognostic value of <i>KRAS</i> exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3549-3549.	0.8	0